Ulipristal acetate 5mg prescribing for uterine fibroids

Below are the database queries which are used to create this measure. These are run against a copy of the BSA prescribing data which we store in Google BigQuery. We're working on making our BigQuery tables publicly available at which point it will be possible to run and modify these queries yourself. But even where code and database queries are not directly useable by others we believe it is always preferable to make them public.

Description Number of items for ulipristal acetate 5mg per 1000 patients
Why it matters The MHRA has a clear safety direction advising that patients taking Esmya (ulipristal acetate) for uterine fibroids should STOP their treatment IMMEDIATELY.

Any prescribing on this measure should prompt investigation to identify patients and ensure the treatment is stopped and followup blood tests arranged.

Please note that this is an experimental measure to support a new type of alert. We would be grateful for any feedback at [email protected].
Tags Safety, Reproductive system
Implies cost savings No
Authored by brian.mackenna
Checked by richard.croker
Last reviewed 2020-04-02
Next review due 2020-10-02
History View change history on GitHub →

Numerator SQL

SELECT
     CAST(month AS DATE) AS month,
     practice AS practice_id,
     SUM(items) AS numerator
 FROM hscic.normalised_prescribing
 WHERE bnf_code IN ("0604012U0AAAAAA", "0604012U0BBAAAA")
 GROUP BY month, practice_id

Denominator SQL

SELECT
     CAST(month AS DATE) AS month,
     practice AS practice_id,
     SUM(total_list_size / 1000.0) AS denominator
 FROM hscic.practice_statistics
 GROUP BY month, practice_id
Feedback